Aminosalicylic acid
Granupas, Neopasalate, Para-aminosalicylic Acid, Parasal, Paser, Rezipas (aminosalicylic acid) is a small molecule pharmaceutical. Aminosalicylic acid was first approved as Parasal sodium on 1982-01-01. It is used to treat crohn disease and tuberculosis in the USA. It has been approved in Europe to treat tuberculosis. The pharmaceutical is active against peroxisome proliferator-activated receptor gamma.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| digestive system diseases | D004066 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Aminosalicylic acid resin complex
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| REZIPAS | Bristol Myers Squibb | N-009052 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| crohn disease | EFO_0000384 | D003424 | K50 |
| tuberculosis | EFO_0000774 | D014376 | A15-A19 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A07: Antidiarrheals, intestinal antiinflammatory/antiinfective agents
— A07E: Intestinal antiinflammatory agents
— A07EC: Aminosalicylic acid and similar agents
J: Antiinfectives for systemic use
— J04: Antimycobacterials
— J04A: Drugs for treatment of tuberculosis
— J04AA: Aminosalicylic acid and derivatives
— J04AA01: 4-aminosalicylic acid
HCPCS
No data
Clinical
No data
Drug
General
| Drug common name | Aminosalicylic acid |
| INN | — |
| Description | 4-aminosalicylic acid is an aminobenzoic acid that is salicylic acid substituted by an amino group at position 4. It has a role as an antitubercular agent. It is an aminobenzoic acid and a member of phenols. It is functionally related to a salicylic acid. It is a conjugate acid of a 4-aminosalicylate(1-). |
| Classification | Small molecule |
| Drug class | anti-inflammatory agents (salicylic acid derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Nc1ccc(C(=O)O)c(O)c1 |
Identifiers
| PDB | — |
| CAS-ID | 65-49-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1169 |
| ChEBI ID | 27565 |
| PubChem CID | — |
| DrugBank | DB00233 |
| UNII ID | — |
Target
Agency Approved
PPARG
PPARG
Organism
Homo sapiens
Gene name
PPARG
Gene synonyms
NR1C3
NCBI Gene ID
Protein name
peroxisome proliferator-activated receptor gamma
Protein synonyms
Nuclear receptor subfamily 1 group C member 3, peroxisome proliferator-activated receptor-gamma 5, peroxisome proliferator-activated receptor-gamma splicing, PPAR-gamma
Uniprot ID
Mouse ortholog
Pparg (19016)
peroxisome proliferator-activated receptor gamma (P37238)
Alternate
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use